The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 7, 2008, Pages 2751-2754

  Mieszczak, Jakub ^a,d   Lowe, Elizabeth S ^b   Plourde, Paul ^c   Eugster, Erica A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c Heritage Gateway Center   (United States)

^d RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; TESTOSTERONE;

ABSENCE OF SIDE EFFECTS; AGE; ALBRIGHT SYNDROME; ARTICLE; BONE AGE; BONE MATURATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; GROWTH RATE; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MULTICENTER STUDY; OVARY; PATIENT COMPLIANCE; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; TREATMENT FAILURE; UTERUS WEIGHT; VAGINA BLEEDING;

EID: 47549102969     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-2090     Document Type: Article

References (15)

1. Albright F, Butler A, Hampton A, Smith P 1937 Syndrome characterized by osteitis fibrosa disseminate, areas of pigmentation and endocrine dysfunction, with precocious puberty in females. N Engl J Med 216:722-746
2. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM 1991 Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688-1695
3. Foster CM 1993 Endocrine manifestations of McCune-Albright syndrome. Endocrinologist 3:359-364
4. Foster CM, Feuillan P, Padmanabhan V, Pescovitz OH, Beitins IZ, Comite F, Shawker TH, Loriaux DL, Cutler Jr GB 1986 Ovarian function in girls with McCune-Albright syndrome. Pediatr Res 20:859-863
5. Eugster EA 2004 Aromatase inhibitors in precocious puberty: rationale and experience to date. Treat Endocrinol 3:141-151
6. Roth C, Freiberg C, Zappel H, Albers N 2002 Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab 15(Suppl 3):945-948
7. Kunz GJ, Mao CS, Gottschalk ME Anastrozole use during precocious puberty in McCune-Albright syndrome. Program of the 85th Annual Meeting of The Endocrine Society, Philadelphia, PA, June 19-20, 2003, p 293 (Abstract P1-673)
8. Buzi F, Pilotta A, Dordoni D, Lombardi A, Zaglio S, Adlard P 1998 Pelvic ultrasonography in normal girls and in girls with pubertal precocity. Acta Paediatr 87:1138-1145
9. Feuillan PP, Jones J, Cutler Jr GB 1993 Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 77:647-651
10. Nunez SB, Calis K, Cutler Jr GB, Jones J, Feuillan PP 2003 Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 88:5730-5733
11. Azim AA, Costantini-Ferrando M, Lostritto K, Oktay K 2007 Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 92:2197-2200
12. Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT 2007 Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. J Clin Endocrinol Metab 92:2100-2106
13. Eugster EA, Rubin SD, Reiter EO, Plourde P, Jou HC, Pescovitz OH 2003 Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: a multicenter trial. J Pediatr 143:60-66
14. Mauras N, Welch S, Rini A, Klein KO 2004 An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys. J Pediatr Endocrinol Metab 17:1597-1606
15. Ariazi EA, Lewis-Wambi JS, Gill SD, Pyle JR, Ariazi JL, Kim HR, Sharma CG, Cordera F, Shupp HA, Li T, Jordan VC 2006 Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant. J Steroid Biochem Mol Biol 102:128-138